Risk Score based on microRNA expression signature is independent prognostic classifier of glioblastoma patients
Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
25322872
DOI
10.1093/carcin/bgu212
PII: bgu212
Knihovny.cz E-zdroje
- MeSH
- algoritmy MeSH
- DNA modifikační methylasy genetika MeSH
- enzymy opravy DNA genetika MeSH
- glioblastom genetika mortalita patologie MeSH
- lidé MeSH
- metylace DNA MeSH
- mikro RNA genetika MeSH
- míra přežití MeSH
- mozek metabolismus MeSH
- nádorové biomarkery genetika MeSH
- nádorové supresorové proteiny genetika MeSH
- nádory mozku genetika mortalita patologie MeSH
- následné studie MeSH
- prognóza MeSH
- proliferace buněk * MeSH
- promotorové oblasti (genetika) genetika MeSH
- retrospektivní studie MeSH
- staging nádorů MeSH
- stanovení celkové genové exprese * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- DNA modifikační methylasy MeSH
- enzymy opravy DNA MeSH
- MGMT protein, human MeSH Prohlížeč
- mikro RNA MeSH
- nádorové biomarkery MeSH
- nádorové supresorové proteiny MeSH
Glioblastoma multiforme (GBM) is the most malignant primary brain tumor. The prognosis of GBM patients varies considerably and the histopathological examination is not sufficient for individual risk estimation. MicroRNAs (miRNAs) are small, non-coding RNAs that function as post-transcriptional regulators of gene expression and were repeatedly proved to play important roles in pathogenesis of GBM. In our study, we performed global miRNA expression profiling of 58 glioblastoma tissue samples obtained during surgical resections and 10 non-tumor brain tissues. The subsequent analysis revealed 28 significantly deregulated miRNAs in GBM tissue, which were able to precisely classify all examined samples. Correlation with clinical data led to identification of six-miRNA signature significantly associated with progression free survival [hazard ratio (HR) 1.98, 95% confidence interval (CI) 1.33-2.94, P < 0.001] and overa+ll survival (HR 2.86, 95% CI 1.91-4.29, P < 0.001). O(6)-methylguanine-DNA methyltransferase methylation status was evaluated as reference method and Risk Score based on six-miRNA signature indicated significant superiority in prediction of clinical outcome in GBM patients. Multivariate Cox analysis indicated that the Risk Score based on six-miRNA signature is an independent prognostic classifier of GBM patients. We suggest that the Risk Score presents promising prognostic algorithm with potential for individualized treatment decisions in clinical management of GBM patients.
Citace poskytuje Crossref.org
